Key Highlights

  • BFLY shares rose approximately 6% in pre-market trading to $7.56, up from a prior close of $7.10.
  • The move comes ahead of the company's second-quarter 2026 earnings release, scheduled before today's opening bell.
  • Shares have rallied more than 70% year-to-date, outpacing the broader Medical Information Systems group and S&P 500.
  • A recent BlackRock 13G/A filing showed a 7.8% stake in the company, underscoring sustained institutional interest heading into the print.

Investor Anticipation Builds Ahead of Earnings

Butterfly Network, Inc. (NYSE:BFLY) shares traded higher in pre-market activity ahead of its second-quarter 2026 earnings release, with investors positioning around continued growth in the company's core ultrasound business. Butterfly is a Burlington, Massachusetts-based digital health company that develops, manufactures, and commercializes handheld, whole-body ultrasound devices powered by its proprietary Ultrasound-on-Chip semiconductor technology.

Ahead of the print, analysts have held a consensus Buy rating on the stock, with expectations centered on continued revenue growth near 21.5% and further narrowing of losses. Investor focus has centered on adoption trends for the company's iQ3 device, growth in its Compass AI enterprise software offering, and progress across its Butterfly Embedded licensing partnerships, which allow third parties to build novel applications on the company's chip platform.

Institutional Interest and Broader Sector Context

The recent disclosure of a 7.8% stake held by BlackRock adds to signs of sustained institutional interest in the stock heading into today's report. Butterfly's platform spans point-of-care ultrasound hardware, cloud-based software subscriptions, AI-powered diagnostic tools, and educational offerings through Butterfly Academy and ScanLab, alongside its broader Butterfly Embedded licensing business targeting non-medical applications of its chip technology.

Butterfly carries a market capitalization of approximately $1.86 billion following the pre-market move, with shares trading within a 52-week range of $1.32 to $9.69. The stock's strong year-to-date performance has outpaced the broader Medical Information Systems group and S&P 500, reflecting growing investor enthusiasm for the company's semiconductor-based approach to ultrasound imaging.

Conclusion

Today's pre-market gain reflects investor positioning ahead of a closely watched earnings report, with the market weighing continued execution on core hardware growth against the company's expanding software and licensing initiatives. Investors will watch today's results and the accompanying conference call for confirmation of these growth trends and any updates to full-year guidance.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.